A biopharmaceutical company focused on developing precision genetic medicines for rare diseases, specializing in RNA-targeted therapeutics and gene therapies, particularly for neuromuscular and central nervous system disorders.
Notice Date
July 17, 2025
—
July 18, 2025
Cambridge
Massachusetts
Boston, Northeast, Metro Southwest
